Swedish company Moberg Pharma has completed the previously announced acquisition of over-the-counter, US brand anaesthetic spray DermoPlast from Prestige Brands for $47.6m.

The anaesthetic spray DermoPlast is used externally for relief of pain and itching from skin chaps and skin injuries and would be sold through Moberg Pharma’s sales channels in the US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is planned to be sold through chain drugstores such as CVS, Walgreens and Rite Aid and at retailers such as Walmart and Target, as well as directly to hospitals.

Moberg Pharma CEO Peter Wolpert said: “The acquisition brings increased economies of scale and complements our portfolio with a strong and profitable dermatology brand.

"The acquisition brings increased economies of scale and complements our portfolio with a strong and profitable dermatology brand."

“We are very pleased with this transaction, which is expected to contribute positively to both our sales and profitability and thereby to our long-term financial target to deliver profitable growth and an EBITDA margin of 25%.”

See Also:

Moberg Pharma used a combination of available cash resources along with recently completed financing to finance the transaction, which was announced last month.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

DermoPlast is to be included among Moberg Pharma’s strategic brands and expected to contribute positively to the company’s profit and cash flow per share.

The company acquired three US over-the-counter brands New Skin, Fiber Choice and PediaCare from Prestige in June last year.

Subsequently, it secured an exclusive right to also acquire DermoPlast from Prestige for an option fee of $1.25m that provides a one-time right to perform an evaluation of the brand on an exclusive basis.